Elastin-derived peptides potentiate atherosclerosis through the immune Neu1-PI3Kγ pathway by Gayral, Stephanie et al.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Elastin-derived peptides potentiate atherosclerosis
through the immune Neu1–PI3Kg pathway
Stephanie Gayral1, Roselyne Garnotel2, Audrey Castaing-Berthou1, Sebastien Blaise2,
Anne Fougerat3, Elodie Berge1, Aurelie Montheil1, Nicole Malet1, Matthias P. Wymann3,
Pascal Maurice2, Laurent Debelle2, Laurent Martiny2, Laurent O. Martinez1,
Alexey V. Pshezhetsky4, Laurent Duca2†, and Muriel Laffargue1†*
1INSERM UMR 1048, I2MC, Baˆt. L3, 1 av Jean-Poulhe`s, BP 84225, 31432 Toulouse Cedex 4, France; 2Laboratoire SiRMa, FRE CNRS 3481 MEDyC, URCA, UFR Sciences Exactes et Naturelles,
Campus Moulin de la Housse, 51687 Reims Cedex 2, France; 3Department of Biomedicine, University of Basel Mattenstrasse 28 CH-4058 Basel, Switzerland; and 4Division of Medical Genetics,
Sainte-Justine University Hospital Research Center, 3175 Cote Ste-Catherine, Montre´al, PQ, Canada H3T 1C5
Received 2 October 2013; revised 25 November 2013; accepted 9 December 2013; online publish-ahead-of-print 19 December 2013
Time for primary review: 36
Aims Elastin is degraded during vascular ageing and its products, elastin-derived peptides (EP), are present in the human blood
circulation. EP binds to the elastin receptor complex (ERC) at the cell surface, composed of elastin-binding protein (EBP),
a cathepsin A and a neuraminidase 1. Some in vitro functions have clearly been attributed to this binding, but the in vivo
implications for arterial diseases have never been clearly investigated.
Methods
and results
Here, we demonstrate that chronic doses of EP injected into mouse models of atherosclerosis increase atherosclerotic
plaque size formation. Similar effects were observed following an injection of a VGVAPG peptide, suggesting that the ERC
mediates these effects. The absence of phosphoinositide 3-kinase g (PI3Kg) in bone marrow-derived cells prevented
EP-induced atherosclerosis development, demonstrating that PI3Kg drive EP-induced arterial lesions. Accordingly, in
vitro studies showed that PI3Kg was required for EP-induced monocyte migration and ROS production and that this
effect was dependent upon neuraminidase activity. Finally, we showed that degradation of elastic lamellae in LDLR2/2
mice fed an atherogenic diet correlated with atherosclerotic plaque formation. At the same time, the absence of the
cathepsin A–neuraminidase 1 complex in cells of the haematopoietic lineage abolished atheromaplaque size progression
and decreased leucocytes infiltration, clearly demonstrating the role of this complex in atherogenesis and suggesting the
involvement of endogenous EP.
Conclusion Altogether, this work identifies EP as an enhancer of atherogenesis and defines the Neuraminidase 1/PI3Kg signalling
pathway as a key mediator of this function in vitro and in vivo.
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1. Introduction
Atherosclerosis is a complex, multi-factorial chronic inflammatory
disease affecting medium- to large-sized arteries. Recent findings have
established a fundamental role for inflammation in mediating the differ-
ent stages of this disease, revealing an attractive diversity of potential
targets that can be exploited in the treatment of this pathology.
During early steps of this age-associated inflammatory disease, infil-
trated monocytes–macrophages by producing cytokines and reactive
oxygen species (ROS) sustain a pro-inflammatory environment in the
subendothelial space, resulting in the progression of fatty streak.
Owing to this local inflammatory context, the extracellular matrix
(ECM) of the arterial wall, mostly composed of the elastin and collagen,
is importantly degraded by proteases secreted by infiltrated neutrophil/
macrophage. For a long time, the ECM was described as providing
support for cells and facilitating the mechanical properties of tissues,
but it is now known to also regulate cell phenotype and fate. In the
last few years, particular attention has been given to the role of elastin
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degradation in physiopathological processes as it has been demon-
strated that the release of elastases drives the production of elastin-
derived peptides (EP) (elastokines) that are proposed to be associated
with arterial pathologies.1 EP are present in the blood of the general
population where their serum concentration fluctuates from the
ng/mL to the mg/mL range depending on both the procedure used for
EP dosage and the type of atherosclerotic disease of the patient.2 –4
Nevertheless, a definitive role for EP in the development of arterial dis-
eases in vivo has not yet been demonstrated. In vitro, EP control a wide
range of biological effects that may play beneficial or deleterious roles
on atherosclerosis development. For example, EP are reported to
induce monocyte migration and ROS production leading to low-density
lipoprotein (LDL) oxidation.5,6 This suggests that they could aggravate
atherosclerosis development in vivo and may play a central role in this
pathology. In contrast, EP are also reported to mediate endothelial
cell nitric oxide production that contributes towards slowing down ath-
eroma plaque formation.7 In smooth muscle cells, EP are also able to
promote cell proliferation, suggesting a potential impact on plaque sta-
bilization in vivo.8 EP is thought to elicit most of these effects by activation
of the elastin receptor complex (ERC) which is formed by the associ-
ation with an elastin-binding protein (EBP) (inactive splicing variant of
b-galactosidase protein) and two membrane proteins: the cathepsin A
(CathA) or protective protein (PP) and the associated neuraminidase
(Neu1). Neu1 was identified as the protein responsible for signal trans-
duction from the ERC leading to the activation of various signalling
modules that differ depending on the cell type.1,9,10 In fibroblasts, ERC
activation leads to recruitment and activation of the phosphoinositide
3-kinase g (PI3Kg), but the mechanism involved remains unknown.11
Interestingly, this kinase is highly expressed in haematopoietic cells
and plays a key role in inflammatory processes of the arterial wall
during atherogenesis.12,13
Here, we have evaluated the role of EP in atherosclerosis progression
and the possible involvement of PI3Kg in this process. In this investiga-
tion, we used two existing murine models of atherosclerosis to
provide direct evidence that EP enhance atheroma plaque size progres-
sion and that this effect could be driven by their action on monocytes
through the Neu1–PI3Kg signalling module. We also show that degrad-
ation of elastic lamellae in LDLR2/2mice put on an atherogenic diet cor-
relates with atherosclerotic plaque formation. At the same time, the
absence of the CathA–Neu1 complex in cells of the haematopoietic
lineage abolishes atheroma plaque size progression and leucocyte infil-
tration, suggesting the involvement of endogenous EP. Altogether our
data show a novel function of elastokines in the development of




The synthetic peptides VGVAPG and VVGPGA were produced by
GeneCust (Luxembourg). The neuraminidase inhibitor 2,3-dehydro-
2-deoxy-N-acetylneuraminic acid (DANA) was purchased from
Sigma-Aldrich (Saint-Quentin Fallavier, France). The p110g antibody
was purchased from Santa-Cruz Biotechnology (distributed by Tebu,
Le Perray en Yvelines, France). Monoclonal antibodies directed against
Akt and phosphorylated Akt (threonine 308), and horse radish peroxy-
dase (HRP)-conjugated anti-rabbit antibodies were purchased from Cell
Signaling Technology (distributed by Ozyme, Saint-Quentin en Yvelines,
France). The enhanced chemiluminescence (ECL) system was purchased
from Amersham Biosciences, Inc. (Orsay, France).
2.2 Mice
PI3K-deficient (PI3Kg2/2) mice were generated from a C57Bl/6J back-
ground as previously described.13– 15 CathAS190A-Neo mice were on a
C57Bl/6J background as previously described.16 As models of in vivo ath-
erosclerosis, C57Bl/6J apolipoprotein E-deficient (ApoE2/2) mice and
C57Bl/6J LDL receptor-deficient (LDLR2/2) mice were obtained
from Charles River Laboratories (Wilmington, MA, USA). Wild-type
(WT), PI3Kg2/2, LDLR2/2, and ApoE2/2 mice were maintained at
the Rangueil Animal Facility of Toulouse (France) and CAS190A-Neo
mice at the animal facilities of the Division of Medical Genetics, Sainte-
Justine University Hospital (Montreal, Canada). These mouse models
were kept under specific pathogen-free conditions. During experi-
ments, mice were anaesthetized using isoflurane (2%) and were eutha-
nized using cervical dislocation.
All animal procedures were in accordance with institutional guidelines
on Animal Experimentation and with a French Ministry of Agriculture
license. Moreover, this investigation conformed to the Guide for the Care
and Use of Laboratory Animals published by the United States National Insti-
tutes of Health or the Directive 2010/63/EU of the European Parliament.
2.3 Kappa-elastin preparation
EP were prepared as described previously.9 Briefly, insoluble elastin
was prepared from bovine ligamentum nuchae by hot alkali treatment.
Its purity was assessed by comparing its amino acid composition to
that predicted by the elastin gene product. Soluble EP were obtained
from insoluble elastin by organo-alkaline hydrolysis. This was achieved
using 1 M potassium hydroxide in 80% aqueous ethanol. The mixture
of EPs obtained is termed kappa-elastin (kE) and exhibits the same bio-
logical and physical properties as elastin hydrolysates obtained using
elastase taken from leucocytes.
2.4 Bone marrow transplantation
Eight-week-old C57Bl/6J LDLR2/2 mice were subjected to medullary
aplasia by 9-Gy total-body irradiation. We re-populated mice with i.v.
injection of bone marrow (BM) cells isolated from the femurs and
tibias of littermate WT or PI3Kg2/2 mice (WTLDLR2/2, PI3Kg2/2
LDLR2/2) and littermate WT or CAS190A-Neo mice (WTLDLR2/2,
CathAS190A-Neo LDLR2/2). After 4 weeks of recovery, mice were
fed a pro-atherogenic diet (15% fat, 1.25% cholesterol, and 0%
cholate) for either an additional 6 weeks for mice reconstituted with
PI3Kg BM, or 12 weeks for mice reconstituted with CathAS190A-Neo
BM. Blood and tissues were collected and analysed as described
below. The successful engraftment was confirmed by PCR.
2.5 Characterization of atherosclerotic
lesions
The hearts were prepared as described previously13 and the athero-
sclerotic lesions were estimated according to Paigen et al.17 Briefly,
the heartwerewashed in phosphate-buffered saline (PBS) and incubated
in PBS at 48C for 12 h. Each heart was frozen on a cryostat mount with
optimum cutting temperature (OCT) compound (Tissue-Tek), and
stored at 2808C. One hundred sections of 10 mm thickness were pre-
pared from the top of the left ventricle, where the aortic valves were first
visible, up to a position in the aorta where the valve cusps were just dis-
appearing from the field. After drying for 2 h, the sections were stained
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with Oil RedO and counterstained with Mayer’s haematoxylin. After Oil
Red O staining, surface lesion areas were measured by computer-
assisted image quantification using the Leica QWin software (Leica
Microsystems, Wetzlar, Germany). Images were captured with a Sony
(Tokyo, Japan) 3CCD video camera.
2.6 Immunohistochemistry
Frozen sections from the aortic root were fixed in acetone/methanol,
air-dried, and incubated with 10% of relevant serum for 30 min. The
following specific primary antibodies were used: anti-monocyte/
macrophage (clone MOMA-2, Serotec, Oxford, UK) and anti-
lymphocyte T/CD3 (clone SP7, Zytomed System, Berlin, Germany).
Then, sections were incubated with the corresponding secondary
biotinylated antibodies (Dako) and visualized with an avidin–biotin–
horseradish peroxidase complex (Vectastain ABC kit, Vector Labora-
tories) and the 3-3′ diaminobenzidine (DAB) peroxidase substrate kit
(DakoCytomation, Glostrup, Denmark). Countercolouration was
performed with Mayer’s haematoxylin. Irrelevant IgGs were used as
negative controls.
2.7 Analysis of plasmatic cholesterol
Cholesterol levels were measured with a commercial kit: CHOD-PAP
(Randox Laboratories, Crumlin, County Antrim, Ireland).
2.8 Murine monocyte ROS production assay
Blood taken from mice was centrifuged (400 g) in the presence of a
mixture of sodium metrizoate [13.8% (w/v)] and dextran 500 [8.0%
(w/v)] (density 1.113 g/L and osmolarity 460 osmol). Monocytes were
then purified and washed in Dulbecco’s solution (NaCl 137 mmol/L,
KCl 2.7 mmol/L, HEPES 30 mmol/L, glucose 10 mmol/L, CaCl2
1.3 mmol/L, MgCl2 1.0 mmol/L, pH ¼ 7.4). Cells were counted and
their purity was assessed following May–Grunwald–Giemsa colour-
ation. For ROS production, nitroblue tetrazolium (NBT) reduction
was used. Cells were stimulated by kE (50 mg/mL), VGVAPG (200 mg/mL),
or BSA in the presence or absence of DANA (200 mM), in the presence
of NBT. Briefly, 104 cells were incubated for 2 h at 378C in 50 mL DMEM
(containing or not the different agonists/inhibitors) in which 5 mL of
NBT (1.36 mg/mL) was added. NBT reduction leads to a loss of positive
charges and to a consequent decrease in its solubility. Its absorption
spectrum is subsequently modified leading from yellow (oxidized
form) to blue (reduced form, formazan). The generated insoluble forma-
zan is directly measured using a spectrophotometer (Tecan Infinite F200
Pro, Lyon, France) by absorbance (560 nm).
2.9 Murine monocyte migration assay
Monocyte migration was evaluated using a Boyden chamber containing
Dulbecco’s solution in the upper compartment and kE (50 mg/mL) or
VGVAPG (200 mg/mL) in the presence or in the absence of DANA
(200 mM) in the lower compartment. After 4 h incubation, the mem-
brane between the two chambers was stained with crystal violet and
cells were counted using a microscope. Ten different fields were
counted for each experiment.
2.10 Western blot analysis
Proteins from blood monocytes were dissolved in Laemmli buffer,
boiled, separatedby SDS–polyacrylamidegel electrophoresis and trans-
ferred onto a nitrocellulose membrane. Immunodetection was achieved
using primary antibodies against Akt phosphorylated on Threonine 308
(1/1000), or total Akt (1/1000) overnight at 48C. Membranes were then
incubated with HRP-conjugated secondary antibody (anti-rabbit,
1/1000) for 1 h at room temperature, then immunoreactive proteins
were detected with ECL reagents according to the manufacturer’s
instructions.
2.11 PI3K activity assay
Cells were washed twice in ice-cold PBS containing 50 mM Na3VO4,
then scraped off into PBS and centrifuged (375 g, 10 min, 48C). Pellets
were resuspended and incubated for 15 min at 48C in immunoprecipitation
Figure 1 EP increase atherosclerosis development in two athero-
sclerotic mouse models. (A–C) Eleven-week-old ApoE2/2 mice
were i.v. injected with EP [kappa-elastin (kE)] (5 mg/kg, n ¼ 7) or
vehicle (PBS, n ¼ 6) once a week for 6 weeks, and then spontaneous
atherosclerosis was studied. (D–F) Eight-week-old LDLR2/2 mice
were fed an atherogenic diet and i.v. injected with kE (5 mg/kg,
n ¼ 7) or vehicle (PBS, n ¼ 7) once a week for 6 weeks. Representative
photomicrographs of Red Oil O-stained fatty streaks (original magnifi-
cation ×50) (A and D) and quantitative analysis of atherosclerotic
lesion sizes (mm2) in the aortic roots of indicated mouse models (B
and E) are presented. Total plasma cholesterol levels were measured
in each indicated mouse model (C and F ). Data represent means+
SEM. *P ≤ 0.05 compared with PBS-treated controls; NS, not signifi-
cantly different from the corresponding control.
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lysis buffer [10 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA, 10% (v/v)
glycerol, 1% (v/v) Brij 98, 1 mM Na3VO4, with added protease inhibitor
cocktail]. An insoluble material was removed by centrifugation
(20 000 g, 20 min, 48C). Protein concentrations were determined
using a bicinchonic acid assay protein assay and equal amounts of pro-
teins were incubated with 10 mg anti-p110g antibodies for 1 h at 48C.
The antigen–antibody complexes were incubated with protein
G-Plus-Sepharose (Santa-Cruz Biotechnology) for 1 h at 48C, col-
lected by centrifugation, washed three times in immunoprecipitation
lysis buffer and then twice with lipid kinase buffer (25 mM HEPES pH
7.4, 100 mM NaCl, 5 mM MgCl2, 200 mM adenosine). To perform
the lipid kinase assay, each pellet was resuspended in 70 mL of lipid
kinase buffer supplemented with phosphatidylinositol (PI) and phos-
phatidylserine (10 mg/mL each), 2.5 mM ATP and 10 mCi
[g-32P]-ATP. The reaction was performed for 15 min at 308C and
stopped by the addition of 100 mL 1 M HCl. Phospholipids were
extracted with 350 mL chloroform/methanol (1:1, v/v), and the
organic phase was washed twice with 200 mL methanol/1 M HCl
(1:1, v/v). Organic phases (110 mL) were spotted onto oxalate-treated
thin layer chromatography (TLC) plates and lipids were then separated
using a chloroform/methanol/acetone/acetic acid/H2O (40:13:15:12:7,
v/v/v/v/v) solvent system. Plates were revealed by autoradiography.
2.12 Elastic fibres breakage analysis
Immediately after sacrifice of mice, thoracic aortas were dissected and
then directly frozen in liquid nitrogen. Four-micrometre cryo-sections
of OCT-embedded samples were rinsed in PBS for 5 min and conserved
with FluorSave TM Reagent (Calbiochem). Autofluorescence of elastin
(lexcitation/lemission: 410/500 nm) was evaluated using a Zeiss micro-
scope (Axio A1).
2.13 Statistical analysis
Comparisons between the different groups were performed using an
unpaired t-test. Statistical differences considered significant were prob-
ability values P ≤ 0.05 (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 compared
with the corresponding control of each experiment). Data are shown
as means+ SEM.
3. Results
3.1 EP accelerate atherosclerosis
development in vivo
To evaluate whether circulating EP play a role in atheroma progression,
we used two murine models of atherosclerosis, apolipoprotein
E-deficient mice (ApoE2/2) and low-density lipoprotein receptor-
deficient mice (LDLR2/2). We used young ApoE2/2 and LDLR2/2
mice in which elastic fibre degradation in their arterial wall is very low
in order to avoid endogenous EP participation (see Supplementary ma-
terial online, Figure 1 A and B). To evaluate the effect of circulating EP in
early atherosclerosis, 11-weeks-old ApoE2/2 mice were injected with
Figure 2 The VGVAPG peptide increases atherosclerosis development. Eleven-week-old ApoE2/2 mice were i.v. injected with the synthetic peptides:
VGVAPG (20 mg/kg, n ¼ 9) or scramble VVGPGA (20 mg/kg, n ¼ 6) or vehicle (PBS, n ¼ 6) once a week for 6 weeks, then spontaneous atherosclerosis
was evaluated. Representative photomicrographs of Red Oil O-stained fatty streaks (original magnification ×50) (A) and quantitative analysis of athero-
sclerotic lesion sizes (mm2) in the aortic roots of ApoE2/2 mice (B) are presented. Total plasma cholesterol levels were measured in each treated mouse
(C). Data represent means+ SEM. **P ≤ 0.01 compared with PBS-treated controls; NS, not significantly different from the corresponding control.
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kE once a week during 6 weeks. kE is an organometallic hydrolysate of
elastin that presents the samebiological effects as ahydrolysate obtained
following digestion of leucocyte elastase. We used a dose of 5 mg/kg kE,
a level of EP similar to that found in the general ‘atherosclerotic’ human
population.3 Analysis of lipid deposition in the aortic root sections of
control mice showed fatty streak lesions (on average covering an area
of 79 000 mm2), which were highly potentiated by EP injection
(155 000 mm2) (Figure 1A and B). Total plasmatic cholesterol levels
were not modified by EP injection, suggesting that the increase in the
lesion size was not accounted for by changes in plasma cholesterol
levels (Figure 1C). In parallel, LDLR2/2 mice were fed an atherogenic
diet for 8 weeks to encourage the development of larger atherosclerotic
lesions (120 000 mm2) (Figure 1D and E) and presented higher levels of
plasmatic cholesterol (Figure 1F). Like ApoE2/2 mice, these mice also
showed a potentiation of atherosclerotic lesion size following EP treat-
ment without any modification of plasmatic cholesterol levels, showing
that EP accelerates the development of atherosclerosis in both models.
Therefore, these results clearly demonstrate that EP accelerates the
initiation of atherosclerosis in vivo.
3.2 VGVAPG peptide accelerates
atherosclerosis development in vivo
It has been established that diverse elastokines containing the XGXXPG
repeat hexapeptide can bind to the ERC and thatVGVAPG is the optimal
ligand for high-affinity binding to this cell surface receptor.18– 20 There-
fore, in order to examine whether EP-induced atherosclerosis is specif-
ically dependent on ERC in vivo, we used the VGVAPG synthetic peptide.
A dose of 20 mg/kg VGVAPG was used since it has been demonstrated
that, compared with kE, a four-fold higher concentration of single
peptide is necessary to achieve the equivalent physiological stimulation
levels of a bioactive EP released following elastin degradation.20,21
ApoE2/2 mice were i.v. injected with VGVAPG peptide or vehicle
(PBS) once a week for 6 weeks (Figure 2). After red-oil staining of
ApoE2/2 mice fatty streaks, we observed that VGVAPG synthetic
peptidespotentiate atherosclerosis progression comparedwith vehicle-
treated mice or to scramble peptide VVGPGA-treated mice (an average
lesion size of 163 572 vs. 98 051 mm2 or 163 572 vs. 89 745 mm2,
respectively). As observed with kE, plasma lipid levels were not affected
by VGVAPG treatment or VVGPGA treatment. Thus, these results
suggest that specific activation of ERC leads to the potentiation of
atherosclerosis.
3.3 Haematopoietic PI3Kg is required
for EP-induced atherosclerosis
Our team haspreviously described thatPI3Kg is a crucial molecular relay
in EP-mediated ERC signalling in fibroblasts.11 Moreover, we have also
provided evidence that loss of PI3Kg function in the haematopoietic
lineage is sufficient to prevent atherosclerosis development.13 Thus,
to evaluate the role of immune PI3Kg in EP-induced atherosclerosis,
we generated a mouse model in which haematopoietic cells exclusively
are devoid of PI3Kg by transplanting BM from PI3Kg-deficient
(PI3Kg2/2) mice to irradiated LDLR2/2-recipient mice (PI3Kg2/2
LDLR2/2). The efficiency of transplantation was established by the
detection of ,5% of LDLR2/2 DNA in BM cells from WT or
PI3Kg2/2 LDLR2/2 mice, indicating a chimerism of 95 to 100% of
cells (see Supplementary material online, Figure 2A and B). These mice
were injected with kE (5 mg/kg) or vehicle (PBS) once a week as
described for Figure 1. Analysis of atherosclerotic plaques in aortic
roots revealed that EP injections into WTLDLR2/2 mice increased
atheroma size compared with control mice (average lesion size
48 276+16 469 vs. 79 056+26 435 mm2) and confirms our results
described in Figure 1 (Figure 3A and B). Interestingly, injection of EP into
PI3Kg2/2 LDLR2/2 mice had no effect on lesion size or plasma
cholesterol levels compared with control mice (Figure 3D, E and F).
Thus, these results suggest that PI3Kg in the haematopoietic lineage
regulates atherosclerosis induced by EP signalling.
Figure3 PI3Kgof the haematopoietic lineage is indispensable for EP
signalling-induced atherosclerosis. Eight-week-old irradiated
LDLR2/2 mice were transplanted with WT BM (WTLDLR2/2,
n ¼ 16) (A–C ) or with PI3Kg-deficient littermate (PI3Kg2/2) BM
(PI3Kg2/2LDLR2/2, n ¼ 15) (D–F); both were fed a
pro-atherogenic diet and i.v. injected with EP [kappa-elastin (kE)]
(5 mg/kg) or vehicle (PBS) once a week for 6 weeks. Representative
photomicrographs of Red Oil O-stained fatty streaks (A and D) and
quantitative analysis of atherosclerotic lesion sizes (mm2) in the
aortic roots of each transplanted LDLR2/2 mouse (B and E) is
shown. Total plasma cholesterol levels were measured in each indi-
cated transplanted mouse (C and F). Data represent means+ SEM.
*P ≤ 0.05 compared with PBS-treated controls; NS, not significantly
different from the corresponding control.
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3.4 PI3Kg and neuraminidase are involved in
EP-induced ROS production and migration
of monocytes
The biological functions of EP first described in monocytes was their
ability to induce the production of ROS and migration, both of which
contribute towards atherogenesis.22– 24 We, therefore, investigated
the possible role of PI3Kg and neuraminidase in these processes.
Thus, circulating monocytes isolated from PI3Kg+/+ and PI3Kg2/2
mice were stimulated in vitro with kE or VGVAPG pre-treated or not
with DANA, a specific neuraminidase inhibitor able to block the bio-
logical activities of the ERC and elastokine-induced signalling9,25
(Figure 4). EP-induced ROS production (Figure 4A andC ) and migration
(Figure 4B and D) were reduced to the same extent by both the
absence of PI3Kg or following treatment with DANA. Moreover,
treatment with DANA had no additional effects on VGVAPG-induced
ROS production and migration in PI3Kg2/2 monocytes (data not
shown), suggesting that PI3Kg and neuraminidase are in the same sig-
nalling pathway. These results show that neuraminidase and PI3Kg are
key transducers of EP-induced ROS production and migration in
monocytes.
3.5 EP control PI3Kg activity in a
neuraminidase-dependant manner
in monocytes
To further delineate the signalling cascades involved in EP stimulation of
monocytes, we measured the impact of DANA on PI3Kg activity. We
measured PI3Kg activity in p110g immunoprecipitates using an in vitro
PI3K activity assay with PI as a substrate and found that kE treatment
increased PI3K activity (Figure 5A). To confirm these results, we evalu-
ated the phosphorylation of Akt, a well-known effector of PI3K lipid
kinase activity. kE treatment increased Akt phosphorylation on threo-
nine 308 without any changes in total Akt expression (Figure 5B), indicat-
ing that PI3K activity was increased by EP stimulation. Interestingly,
pre-treatment with DANA reduced EP-induced activity back to
control levels (Figure 5A and B), demonstrating that neuraminidase activ-
ity is a pre-requisite for EP-induced activation of PI3Kg in monocytes.
Figure4 Loss of PI3Kgexpression and Neu inhibition reducesROS production and migration in monocytes. (A andB) Monocytes were purified fromthe
blood of PI3Kg+/+ (n ¼ 5) or PI3Kg2/2 (n ¼ 5) mice and were stimulated withkE (50 mg/mL) or VGVAPG peptide (200 mg/mL) for either 2 h to measure
ROS production (A) or 4 h to measure migration (B) in each indicated condition. Data represent means+ SEM. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001
compared with WT monocytes stimulated with the same agonists. NS, not significantly different from the corresponding control. (C and D) PI3Kg+/+
monocytes (n ¼ 5) were stimulated with kE (50 mg/mL) or VGVAPG peptide (200 mg/mL) in the presence or absence of DANA (200 mM), and then
ROS production (C) or migration (D) were measured in each indicated condition. Data represent means+ SEM. *P ≤ 0.05, **P ≤ 0.01, and
***P ≤ 0.001 compared with WT monocytes stimulated with the same agonist, NS, not significantly different from the corresponding control.
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3.6 Decreased Neu1 activity in the
haematopoietic lineage is sufficient to
reduce atherosclerosis in LDLR2/2 mice
During the inflammatory response in the progression of atherosclerosis,
elastinolytic enzymes are released which cleave insoluble elastin within
the arteries to generate endogenous EP.26 To better identify the dynam-
ics for EP appearance, we observed elastic lamellae degradation in
LDLR2/2 mice fed an atherogenic diet for 6 or 12 weeks using elastin
autofluorescence analysis.27 No degradation was observed after 6
weeks of atherogenic diet but by 12 weeks elastic lamellae appeared
totally degraded, indicating that EP production occurred predominantly
after 6 weeks (Figure 6A).
To assess the role of Neu1 in atherosclerosis induced by endogenous
EP in vivo,wegeneratedamousemodelwithcatalytically defectiveNeu1 in
haematopoietic cells by BM transplant from CathA/Neu1-deficient mice
(CathAS190A-Neo mouse) to irradiated LDLR2/2-recipient mice
(CathAS190A-Neo  LDLR2/2). These CathAS190A-Neo mice presented
a 90% reduction in Neu1 activity in leucocytes compared with WT
cells.16,28 Transplantation efficiency was verified by the detection of
,5% of LDLR2/2 DNA in BM cells from CathAS190A-Neo  LDLR2/2
mice, attesting a high percentage of donor BM recovery (see Supple-
mentary material online, Figure 2A and C). Plasma lipid analysis of
CathAS190A-Neo  LDLR2/2 mice fed an atherogenic diet for
12 weeks showed no modification compared with LDLR2/2 mice trans-
planted with WT BM(WTLDLR2/2) (Figure 6B). In contrast analysis of
lipid deposition in aortic roots section showed dramatic decrease in the
lesion size in CathAS190A-Neo  LDLR2/2 mice compared control
mice (Figure 6C). Moreover, cellular composition of atherosclerotic
lesion showed an important reduction of monocytes and lymphocytes
infiltration in the absence of CathA–Neu1 complex (Figure 6D and E).
Altogether, these data indicate that haematopoietic Neu1 expression is
indispensable in the formation of atherosclerotic lesions in mice.
4. Discussion
EP are one of the major products of ECM degradation that occurs during
inflamm-aging, and now a growing body of evidence suggests that they
can also affect adjacent/circulating cells and contribute to the progres-
sion of age-associated chronic inflammatory diseases such as athero-
sclerosis.1,29 Despite this, an active function for EP in the induction of
atheroma plaque progression is yet to be clearly demonstrated. Here,
we provide clear evidence that circulating EP are enhancers of athero-
sclerosis development in two different mouse models of atheroscler-
osis. Serum concentrations of EP fluctuate from the ng/mL to the mg/
mL range depending on the procedure used for EP dosage and the
type of atherosclerotic disease of the patients.2,4,30 Thus, we injected
mice with a dose of EP corresponding to the elevated doses found in
the circulating blood of the human ‘atherosclerotic’ population,2
taking into consideration that 50% of the injected EP was measured in
the urine of mice 1 h after injection and that 1 day after injection
,10% was detected in the blood.31 Indeed, it has been described that
a circulating dose of 0.5 mg/kg EP can be detected in the blood of
general atherosclerotic human population.2 Therefore, the injection of
5 mg/kg kE leads in 24 h to the same concentration found in humans.
The inductive effect on atherosclerosis development was also
observed after injection of a synthetic peptide VGVAPG which is
known to bind with high avidity to EBP19 and transduce signalling path-
Figure5 Neuraminidase is responsible for PI3Kg signalling in mono-
cytes. Blood monocytes were purified from PI3Kg+/+mice, stimulated
with kE (15 min, 50 mg/mL) in the presence or in the absence of
DANA. (A) An equal amount of protein was subjected to immunopre-
cipitation using antibodies against the catalytic subunit of PI3Kg
(p110g). Immunoprecipitates were incubated with a mixture of PI/
phosphatidylserine/[g32P] ATP and PI3P production was measured
as an indicator of PI3K activity. Thin layer chromatography (TLC)
from representative experiments and densitometry analyses is
shown (means+ SEM, n ¼ 3). **P ≤ 0.01 compared with unstimu-
lated cells. (B) Lysates from blood monocytes were analysed by
western blot analysis using antibodies against phosphorylated Akt
(threonine 308)or total Akt. Immunoblots fromrepresentativeexperi-
ments and densitometry analyses are shown (means+ SEM, n ¼ 3).
**P ≤ 0.01 compared with unstimulated cells.
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Figure 6 Reduced artherosclerotic lesion size in LDLR2/2 mice devoid of Neu1 in immune cells. (A) Evaluation of elastic fiber degradation during ath-
erosclerotic ageing in LDLR2/2mice. Autofluorescence of elastin was analysed by epifluorescence from cryo-sections (4 mm) of aorta samples in order to
determinate elastic fibre breakage. (B–E) Eight-week-old irradiated LDLR2/2mice were transplanted with WT BM (WTLDLR2/2, n ¼ 6) or with CA/
Neu1-deficient littermate (CathAS190A-Neo) BM (CathAS190A-NeoLDLR2/2, n ¼ 5) and fed a pro-atherogenic diet for 12 weeks. Total plasma choles-
terol levels were measured in each indicated transplanted mouse (B). Atherosclerotic lesion sizes in the aortic roots of each transplanted LDLR2/2 mice
were analysed and quantified after Red Oil O-staining of the fatty streaks (C). Adjacent sections of aortic root with atherosclerotic lesion were stained with
anti-monocytes/macrophages (clone MOMA-2) (D) and anti-CD3 (T lymphocyte) antibodies (E). Data represent means+ SEM. *P ≤ 0.05 compared with
WTLDLR2/2 mice . NS, not significantly different from the corresponding control.
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ways through the ERC. Moreover, this effect was not observed in mice
treated with the VVGPGA scramble peptide, suggesting that binding of
EP to the ERC is involved in atherosclerosis progression in mice. In
humancells, ERChasbeen identifiedas anheterotrimeric receptorcom-
posed of a peripheral 67 kDa EBP, which is a spliced variant of
b-galatosidase and specifically binds EP, a 55 kDa PP/CathA and a
61 kDa membrane-bound Neu1 which is the active part of the recep-
tor.25 Two other EP receptors have been identified to date: the integrin
avb3 and galectin-3,
32 but their in vivo relevance is yet to be demon-
strated. Moreover, neither is known to have associated sialidase activity
like that of Neu1 in the ERC. Consequently, our results can discriminate
between the different elastin receptors. As discussed below, we show
here that the pro-atherosclerotic effect of EP relies on sialidase activity
and a CathA–Neu1 complex, demonstrating a role for the ERC. These
results are in par with recently published data implicating the ERC in the
induction of type 2 diabetes in a mouse model through Neu1-dependent
signalling,31 confirming a physiological role for the ERC despite the fact
that the identityof the EBP in the mouseERC complex remains to be elu-
cidated. Depending on the cell type, stimulation of the ERC by EP
induces activation of various signalling modules.33 In dermal fibroblasts,
we have previously shown that PI3Kg is essential for activation of the
Raf-1/MEK1/2 module following EP stimulation.11 Interestingly, this
isoform of PI3K is highly expressed in immune cells and we and others
have shown that it is essential for the inflammatory processes of arterial
wall during atherosclerosis development.13,34,35 We, therefore,
hypothesized that this kinase could be the link between ERC and
atherosclerosis development. Consistent with these previous data, we
conducted transplantation experiments with WTLDLR2/2 and
PI3Kg2/2LDLR2/2 mice and found that EP were unable to potenti-
ate atherosclerosis development in the absence of immune PI3Kg.
These results demonstrate for the first time that PI3Kg is a key signalling
protein involved in EP-induced atherosclerosis in vivo. Moreover, this
result reveals one of the possible mechanisms by which PI3Kg drives
atherosclerosis.
Acting downstream of chemokine receptors, PI3Kg, plays a major
role in modulating the inflammatory functions of immune cells.36 This
kinase is especially indispensable in leucocyte migration in response to
chemokines and in the oxidative burst of monocytes in response to
fMLP (formyl-methionyl-leucyl-phenylalanine).14,37 Since in vitro
studies have demonstrated that EP exert a powerful chemotactic
effect on monocytes and stimulate their free-radical production23,38
we investigated the possibility that PI3Kg relays signals in both of
these biological functions during atherogenesis. Our in vitro experiments
performed in WT- and PI3Kg-deficient monocytes provide evidence
that neuraminidase activity is essential for PI3Kg-mediated induction
of both functions, but the mechanism by which PI3Kg is activated
remains to be elucidated. One hypothesis is that Neu1-dependent lacto-
sylceramide production described as a central messenger in ERC signal-
ling10 is linked to the heterotrimeric Gi proteins that are involved in
PI3Kg activation and are known as targets of the ERC.1 This glycosphin-
golipid is reported to directly regulate Lyn activation through interaction
via its acyl chains. It is thought that the hydrophobic chains of lactosylcer-
amide protrude into the cytoplasmic membrane leaflet and direct van
der Waals interactions between itself and the acyl chains of Lyn
leading to a conformational modification and activation of Lyn.39 It is
conceivable that the same mechanism applies in the regulation of
other acyl chain-anchored proteins such as Gi proteins or other signal
tranducers, as has been previously suggested.40 In addition to their
pro-inflammatory effects on monocytes, it has been shown that EPs
are able in vitro to polarize T cells that express EBP on their surface, shift-
ing them towards the Th1 response.41 Regarding the importance of this
subpopulation of T cells in atherogenesis,42 we investigated the possible
effect of EP in Th1 response in vivo. Analysis of the expression of T-bet
and TIM-3 expression, both transcription factor specifically activated
in Th1 cells, did not show any modification in EP-treated LDLR2/2
mice compared with LDLR2/2 mice, suggesting that EP were not
involved in adaptive immunity during atherogenesis (data not shown).
However, it is worth noting that injection of EP represents an artificial
model and that the pulse/loading-dose effect of external administration
may trigger mechanisms not involved in spontaneous disease. These
points bring out the limit of such approach necessitating validation of
these data using an endogenous model of EP production.
During the inflammatory response, the release of elastases by leuco-
cytes infiltrating the arterial wall at the site of injury contributes to an in-
crease in the cleavage of insoluble elastin, generating endogenous EP and
thus leading to the development of atherosclerosis. We observed aclear
degradationof the integrity of elastic lamellae in the arteries of LDLR2/2
mice fed an atherogenic diet, suggesting that during atheroma size pro-
gression there is a local production of EP in the arterial wall. Previous
work conducted in vitro showed that the removal of b-Gal or PP/
CathA hinders the formation of active Neu143 and that Neu1 is an indis-
pensable component of a functional ERC to relay the EP signalling
response.9 To evaluate the effect of endogenous EP on atherosclerosis
development, we used a mouse model devoid of CathA/Neu1 catalytic
activity in immune cells. Our results demonstrate that a functional
immune ERC is indispensable for driving atherosclerosis development,
suggesting that Neu1 is essential for mediating the response of endogen-
ous EP in this context. Moreover, decreased infiltrated leucocytes in the
absence of Neu1 in haematopoietic lineage suggest that endogenous EP
is involved in chemotactism of immune cells reinforcing our in vitro data.
Nevertheless, it is important to note that the CathA–Neu1 complex is
also involved in lysosomal function and other plasma membrane bio-
logical processes outside the ERC.44 Indeed, the ERC derives from a
lysosomal degradation complex of b-gal–CathA–Neu1. The gener-
ation of a CathAS190A-Neo mouse leads to the absence of CathA expres-
sion and a drastic reduction in Neu1 activity16 which affects EP
signalling since Neu1 transduces its signal, but other biological
processes are also affected.
In summary, this work has identified EP as an enhancer of atherogen-
esis and defines Neu1–PI3Kg as key mediators of this function, driving
the monocyte response to EP. Taken together, our data further illustrate
the critical importance of controlling the production of endogenous EP
and their signalling downstream of the ERC in the progression of arterial
disease.
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